Scarica l'app Stockscreener
9.05
0.22%
-0.02
Precedente Chiudi:
$9.07
Aprire:
$9.09
Volume 24 ore:
40,416
Relative Volume:
0.54
Capitalizzazione di mercato:
$128.87M
Reddito:
-
Utile/perdita netta:
$-8.89M
Rapporto P/E:
-12.93
EPS:
-0.7
Flusso di cassa netto:
$-6.48M
1 W Prestazione:
+0.00%
1M Prestazione:
-8.12%
6M Prestazione:
-19.41%
1 anno Prestazione:
-46.03%
Intervallo 1D:
$8.97
$9.60
Intervallo di 1 settimana:
$8.6701
$9.60
Portata 52W:
$8.06
$18.15
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Nome
Greenwich Lifesciences Inc
Settore
Industria
Telefono
203-434-3290
Indirizzo
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Confronta GLSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
9.05 | 128.87M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-01 | Iniziato | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Borsa (GLSI) Ultime notizie
(GLSI) Technical Data - news.stocktradersdaily.com
How to Take Advantage of moves in (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Acquired by Northern Trust Corp - Defense World
Vanguard S&P 500 Value ETF (NYSEARCA:VOOV) Shares Purchased by Northern Trust Corp - Defense World
Greenwich Lifesciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. SEC 10-Q Report - TradingView
Greenwich LifeSciences Delays Q1 2025 Report Filing - TipRanks
Barclays PLC Raises Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
Long Term Trading Analysis for (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences: What The Recent Data Do For The Investment Thesis (GLSI) - Seeking Alpha
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Acquired by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Purchases 54,551 Shares of System1, Inc. (NYSE:SST) - Defense World
Renaissance Technologies LLC Trims Stock Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) - Defense World
(GLSI) Technical Pivots with Risk Controls - news.stocktradersdaily.com
HC Wainwright Issues Pessimistic Estimate for GLSI Earnings - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright - Defense World
Greenwich LifeSciences stock target raised to $39 at H.C. Wainwright By Investing.com - Investing.com Canada
H.C. Wainwright Boosts Greenwich LifeSciences (GLSI) Price Targe - GuruFocus
(GLSI) Proactive Strategies - news.stocktradersdaily.com
Greenwich Lifesciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Greenwich LifeSciences, Inc. SEC 10-K Report - TradingView
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Monday - Defense World
GREENWICH LIFESCIENCES Earnings Preview: Recent $GLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Greenwich Lifesciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock - Investing.com
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock By Investing.com - Investing.com UK
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock - Investing.com Australia
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial - Curetoday
Greenwich LifeSciences reports progress on FLAMINGO-01 trial By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges - Investing.com
Greenwich Lifesciences Provides Global Update On Flamingo-01 - marketscreener.com
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress on FLAMINGO-01 trial - Investing.com
Major Breakthrough: Cancer Prevention Trial Reports Positive Data, Elite Hospitals Join - Stock Titan
Greenwich LifeSciences (GLSI) Shares Surge on Positive Phase 3 D - GuruFocus
Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech
Pre-market Movers: IBG, JYD, SBFM, SPWH, RSLS… - RTTNews
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times
Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener
Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat
Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st
Greenwich LifeSciences Delays Yearly Report Filing - TipRanks
How To Trade (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire
Greenwich Lifesciences Inc Azioni (GLSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Greenwich Lifesciences Inc Azioni (GLSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
| Patel Snehal | CEO and CFO |
Jan 06 '25 |
Buy |
13.31 |
1,100 |
14,641 |
5,548,202 |
| Patel Snehal | CEO and CFO |
Jan 03 '25 |
Buy |
12.95 |
3,400 |
44,030 |
5,547,102 |
| Patel Snehal | CEO and CFO |
Jan 02 '25 |
Buy |
11.97 |
2,000 |
23,940 |
5,543,702 |
| Patel Snehal | CEO and CFO |
Dec 31 '24 |
Buy |
11.36 |
2,400 |
27,264 |
5,541,702 |
| Patel Snehal | CEO and CFO |
Dec 30 '24 |
Buy |
11.12 |
3,200 |
35,584 |
5,539,302 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):